Towa Pharmaceutical Revises Financial Objectives Amid Strong Performance

Towa Pharmaceutical Co ( (JP:4553) ) has issued an update.

Towa Pharmaceutical Co., Ltd. has revised its financial objectives for its 6th Medium-term Business Plan (2024-2026) due to better-than-expected financial results for the fiscal year ending March 2025. The company anticipates an increase in operating profit, driven by enhanced production capacity at the Yamagata Plant and improved cost optimization strategies, including R&D expenses. The revisions reflect the company’s commitment to increasing corporate value while maintaining its strategic challenges, policies, and themes.

The most recent analyst rating on (JP:4553) stock is a Hold with a Yen3000.00 price target. To see the full list of analyst forecasts on Towa Pharmaceutical Co stock, see the JP:4553 Stock Forecast page.

More about Towa Pharmaceutical Co

Towa Pharmaceutical Co., Ltd., based in Kadoma, Osaka, is a company engaged in the pharmaceutical industry, focusing on the development, production, and distribution of generic drugs. The company aims to enhance its market presence and corporate value through strategic business plans.

Average Trading Volume: 121,118

Technical Sentiment Signal: Hold

Current Market Cap: Yen130.6B

For an in-depth examination of 4553 stock, go to TipRanks’ Stock Analysis page.